Navigation Links
Halozyme and Intrexon Announce Collaboration to Develop First Subcutaneous Recombinant Alpha 1-Antitrypsin Replacement Therapy
Date:6/6/2011

SAN DIEGO and FOSTER CITY, Calif., June 6, 2011 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) and Intrexon Corporation, today announced the signing of a worldwide exclusive licensing agreement for the use of rHuPH20 (recombinant human hyaluronidase) in the development of a subcutaneous (under the skin) injectable formulation of Intrexon Corporation's recombinant human alpha 1-antitrypsin (rHuA1AT). Under terms of the agreement, Halozyme may receive up to $63 million, commencing with an upfront payment of $9 million and total potential future milestone payments of $54 million dependent upon the achievement of clinical and regulatory targets, plus up to 11% royalty on future sales of the combination of rHuA1AT with rHuPH20. The license provides Intrexon Corporation, a next generation synthetic biology company, with exclusivity to alpha 1-antitrypsin, for the indications resulting from A1AT deficiency. Additional terms of the transaction have not been disclosed.

(Logo:  http://photos.prnewswire.com/prnh/20110606/LA14886LOGO)

(Logo:  http://photos.prnewswire.com/prnh/20100302/LA63139LOGO)

Alpha 1-antitrypsin is a protease inhibitor that provides a protective effect from inflammatory cell proteases, especially neutrophil elastase. Intrexon is using its synthetic DNA platform for high-level expression of recombinant A1AT for the potential treatment of diseases resulting from genetic alpha 1-antitrypsin deficiency such as genetic emphysema. A1AT may also benefit patients with chronic obstructive pulmonary disease (COPD) and cystic fibrosis. Currently there is no A1AT recombinant protein available and,
'/>"/>

SOURCE Halozyme Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Halozyme Therapeutics and ViroPharma Announce $83 Million Global Licensing Agreement to Develop Subcutaneous Cinryze® (C1 esterase inhibitor [human])
2. ViroPharma and Halozyme Announce Collaboration for Combination of Recombinant Human Hyaluronidase Enzyme (rHuPH20) Technology with C1 Esterase Inhibitor
3. Halozyme Therapeutics to Present at the Bank of America Merrill Lynch Health Care Conference on May 12
4. Halozyme Therapeutics to Host First Quarter 2011 Financial Results Conference Call on May 6
5. Halozyme Therapeutics Reports Fourth Quarter and Year End 2010 Financial Results
6. Halozyme Therapeutics to Host Fourth Quarter and 2010 Financial Results Conference Call on March 11
7. Halozyme Therapeutics to Present at J.P. Morgan Healthcare Conference on January 12
8. Halozyme Therapeutics Realigns Management
9. Halozymes rHuPH20 With Recombinant Human Insulin Demonstrates Glycemic Control Comparable to Lispro
10. Halozyme Therapeutics Announces Implementation of Development Focused Strategy
11. Halozyme Therapeutics to Host Analyst Meeting on October 14 in New York
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)...  The Leukemia & Lymphoma Society (LLS) is committing ... a joint venture between ImmunGene and Caliber, to co-fund ... I clinical trial for a novel fusion protein that ... with indolent lymphomas who do not respond to standard ... is a new class of biotherapeutics produced by fusing ...
(Date:5/22/2013)... 22, 2013 The new 13-valent pneumococcal conjugate ... previous version used prior to 2010, the 7-valent pneumococcal ... published today in Vaccine. The U.S. Food ... 2010 after a series of trials. These trials found ... pneumococcal types than the previously used PCV7, did not ...
(Date:5/22/2013)... NEW YORK , May 22, 2013 ... Gross LLP is investigating claims on behalf of investors ... (NASDAQ: ISRG ) (CUSIP: 46120E602) who purchased ... April 18, 2013 (the "Class Period"). Such investors are ... at rswilloughby@pomlaw.com or 888-476-6529, ext. 237. ...
Breaking Medicine Technology:The Leukemia & Lymphoma Society, Valor Biotherapeutics and ImmunGene Create Partnership to Advance Novel Therapy for Non-Hodgkin Lymphoma Patients 2The Leukemia & Lymphoma Society, Valor Biotherapeutics and ImmunGene Create Partnership to Advance Novel Therapy for Non-Hodgkin Lymphoma Patients 3The Leukemia & Lymphoma Society, Valor Biotherapeutics and ImmunGene Create Partnership to Advance Novel Therapy for Non-Hodgkin Lymphoma Patients 4Kaiser Permanente Study Finds New Pneumococcal Vaccine Appears to be as Safe as Previously Used Vaccine 2Kaiser Permanente Study Finds New Pneumococcal Vaccine Appears to be as Safe as Previously Used Vaccine 3Kaiser Permanente Study Finds New Pneumococcal Vaccine Appears to be as Safe as Previously Used Vaccine 4SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Intuitive Surgical, Inc. - ISRG 2
... Hosted IT Environment Allows Growth of The ... Across the UK A community-based healthcare service provider ... outsourced its IT infrastructure to Cloud services specialist InTechnology so ... by the NHS, The Practice started with only a handful ...
... Wash., Dec. 7, 2011   Talyst has released ... color-coded barcodes. The bar code technology ensures virtually 100% ... human-readable label. The improved AutoLabel is ... standard black and white transfer labels to improve patient ...
Cached Medicine Technology:NHS Contractor Outsources IT to Focus on Delivering Patient Care 2NHS Contractor Outsources IT to Focus on Delivering Patient Care 3Talyst Updates Its AutoLabel® Solution 2
(Date:5/22/2013)... HealthDay Reporter , , WEDNESDAY, May 22 (HealthDay News) -- ... of suffering, but new research indicates the combination of ... -- a smaller brain. , , Already aware that ... scientists wanted to determine if having both conditions together ... about 2 percent -- isn,t alarming, study authors said, ...
(Date:5/22/2013)... Phelps Memorial Hospital Center in ... Nodule Center for individuals who would like to be ... cancer is the deadliest form of cancer for both men ... die from lung cancer than from breast, colon and prostate ... increases survival rates. It is well established that routine ...
(Date:5/22/2013)... Registered Dietitian and Founder of Tatalou Science Nathalie ... a recipe for making energy bars at home. , The ... takes a recipe modified from one recently featured on ... it gets more and more difficult to understand what ingredients ... of the nutrition label continues to grow and consumers are ...
(Date:5/22/2013)... HR Strategies recently participated in the Gwinnett ... Fairgrounds, on Friday May 10, 2013. For never having ... raising over $6,300 for cancer research. , HR ... the first $3,000 for Bronze Level Sponsorship. HR Strategies ... to match the company’s contribution of $3,000; and after ...
(Date:5/22/2013)... Go Classy the Original Nudist Travel ... of their newest website http://www.Desire-Mexico.com . The seductively ... Desire Resorts have become the premier Nudist and Lifestyle ... total liberation while allowing you to enjoy a deluxe ... Classy Tours / Caribbean-Hideaways. He goes on to say ...
Breaking Medicine News(10 mins):Health News:Having Both Migraines, Depression May Mean Smaller Brain 2Health News:Having Both Migraines, Depression May Mean Smaller Brain 3Health News:Phelps Memorial Hospital Center Establishes The Westchester Lung Nodule Center To Diagnose And Administer Lung Cancer Care 2Health News:Phelps Memorial Hospital Center Establishes The Westchester Lung Nodule Center To Diagnose And Administer Lung Cancer Care 3Health News:How To "Make Your Own Healthy Energy Bars" 2Health News:HR Strategies Raises Over $6,300 for Cancer Research via Relay For Life 2Health News:Go Classy Tours Announces the Launch of Their Newest Website for Desire Resorts Located in Mexico Clothing Optional/Aunaturel Resorts a Lovers Paradise 2
... could soon be offered better treatment thanks to a new ... The University of Nottingham. A purpose-built MRI research ... diseases. The unit is based at the Queens Medical Centre ... of patients using a new, specifically-adapted MRI scanner. ...
... may yield insight into therapies for people, researchers say ... with cancer could provide crucial insight into the human ... and screening for tumors, researchers from the U.S. National ... findings appear in the Oct. 13 online journal ...
... REDONDO BEACH, Calif., Oct. 13 Function Drinks announced ... signed onto the faculty of the Hospital for Special ... as a clinical instructor and attending in spinal surgery. ... research and development for Function Drinks, a line of ...
... SPRING, Texas, Oct. 13 Go Healthy, Inc. (Pink Sheets: ... agreement with Hydro Enterprises, Inc., and Planet Green Solutions, Inc., ... that produces water from any source at a 9.5 pH ... , The ability to place the machines in bottling plants ...
... Oct. 13 Interleukin Genetics, Inc. (NYSE Amex: ILI ) ... of obesity and osteoporosis at medical meetings later this month. The ... and Nutrition Conference & Expo in Denver, Colo. , ... World Diabetes Congress - Montreal, Canada . , Date: ...
... Berger, Managing Member and Founder of Omni Management ... new office in Midtown Manhattan, located at 1120 Avenue of ... strategic geographic expansion," said Berger, "because it just makes good ... , Omni Management Group, LLC ...
Cached Medicine News:Health News:A new scan for lung diseases 2Health News:Dogs Helping to Advance Cancer Research 2Health News:Function Drinks' President & Co-Founder, Dr. Alex Hughes, Joins the Faculty of Cornell's Hospital for Special Surgery 2Health News:Go Healthy Secures Nationwide Distributorship Rights to Patented Drinking Water 2Health News:Go Healthy Secures Nationwide Distributorship Rights to Patented Drinking Water 3Health News:Interleukin Genetics to Present Research Findings at Upcoming Medical Meetings 2Health News:Interleukin Genetics to Present Research Findings at Upcoming Medical Meetings 3Health News:Omni Management Group Announces Opening of New York Office 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: